An Evidence Mapping Study Based on Systematic Reviews of Traditional Chinese Medicine for Hyperuricemia

Why It Matters

The findings highlight a potential complementary role for TCM in hyperuricemia management, but the weak evidence base limits clinical adoption and underscores the need for higher‑quality research.

Key Takeaways

• TCM and ITCW lowered serum uric acid more than Western medicine alone
• Adverse event rates were lower with TCM/ITCW versus standard therapy
• All systematic reviews received a critically low AMSTAR 2 rating
• GRADE certainty for most outcomes was low or very low

Pulse Analysis

Hyperuricemia, affecting millions worldwide, drives gout, kidney disease, and cardiovascular risk. Conventional agents such as allopurinol and febuxostat lower serum uric acid but are plagued by hepatic, renal, and gastrointestinal side effects, prompting patients and clinicians to explore alternative options. In China, where Traditional Chinese Medicine (TCM) is deeply embedded in healthcare, numerous herbal formulas and single‑herb extracts claim to modulate uric acid metabolism through xanthine oxidase inhibition, urate transporter regulation, and anti‑inflammatory pathways. This cultural and therapeutic backdrop has spurred a growing body of systematic reviews assessing TCM’s efficacy and safety for hyperuricemia.

The umbrella review synthesized eleven systematic reviews covering 12,228 participants and identified consistent signals: TCM monotherapy and integrated TCM‑Western regimens produced greater reductions in serum uric acid and higher total effective rates than Western medicine alone, while reporting fewer adverse reactions. Nevertheless, methodological scrutiny revealed pervasive shortcomings. Every review failed to register a protocol, omitted lists of excluded studies, and fell short on critical PRISMA items such as funding disclosure and conflict‑of‑interest statements. Consequently, AMSTAR 2 classified all as critically low quality, and GRADE assigned low or very‑low certainty to most outcomes, largely due to risk‑of‑bias and heterogeneity in the underlying RCTs. These flaws dilute confidence in the apparent therapeutic advantage and raise concerns about selective reporting.

For clinicians, the current evidence suggests that TCM may serve as an adjunctive option for patients intolerant to standard drugs, provided that treatment is closely monitored and patients are informed about the limited evidence quality. Researchers must prioritize rigor: prospective trial registration, adherence to CONSORT and PRISMA guidelines, robust randomization, blinding, and transparent reporting of adverse events. Health‑economic analyses and long‑term follow‑up studies are also essential to determine whether TCM can deliver sustainable, cost‑effective benefits in hyperuricemia care. Until such high‑quality data emerge, TCM should be positioned cautiously within evidence‑informed treatment algorithms.